Related references
Note: Only part of the references are listed.Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy
N. S. Ferder et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
A-G-4G haplotype of PAI-1 gene polymorphisms-844 G/A, HindIII G/C, and-675 4G/5G is associated with increased risk of ischemic stroke caused by small vessel disease
M. G. Adamski et al.
ACTA NEUROLOGICA SCANDINAVICA (2009)
The largest prospective warfarin-treated cohort supports genetic forecasting
Mia Wadelius et al.
BLOOD (2009)
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy
Virginia Perez-Andreu et al.
BLOOD (2009)
A genome-wide association study of acenocoumarol maintenance dosage
Martina Teichert et al.
HUMAN MOLECULAR GENETICS (2009)
C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of ischemic stroke in Polish subjects
I. Goracy et al.
JOURNAL OF APPLIED GENETICS (2009)
Pharmacogenetics in Cardiovascular Antithrombotic Therapy
Francisco Marin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
Fumihiko Takeuchi et al.
PLOS GENETICS (2009)
Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose
Cristi R. King et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Factor VII-323 decanucleotide D/I polymorphism in atrial fibrillation: Implications for the prothrombotic state and stroke risk
Vanessa Roldan et al.
ANNALS OF MEDICINE (2008)
CYP4F2 genetic variant alters required warfarin dose
Michael D. Caldwell et al.
BLOOD (2008)
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement
Danxin Wang et al.
BLOOD (2008)
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
Gregory M. Cooper et al.
BLOOD (2008)
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
B. F. Gage et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation
Margaret C. Fang et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Genetic determinants of response to warfarin during initial anticoagulation
Ute I. Schwarz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues
Brian F. Gage et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2008)
The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol
R. Gonzalez-Conejero et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Valentin Fuster et al.
CIRCULATION (2006)
Fibrinolytic gene polymorphism and ischemic stroke
K Jood et al.
STROKE (2005)
Association of polymorphisms of platelet membrane integrins αIIbβ3 (HPA-1b/PlA2) and α2β1 (α2807TT) with premature myocardial infarction
RB Zotz et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
MJ Rieder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy
F Peyvandi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
S Rost et al.
NATURE (2004)
Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation
SK Thambidorai et al.
AMERICAN JOURNAL OF CARDIOLOGY (2004)
Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation
F Marín et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2004)
The risk of overanticoagulation in patients with cytochrome P450CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon
LE Visser et al.
PHARMACOGENETICS (2004)
Genetic Polymorphisms and thromoembolic risk in atrial fibrillation
F Marín et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2004)
Atrial fibrillation and hypercoagulability: Dependent on clinical factors or/and on genetic alterations?
E Hatzinikolaou-Kotsakou et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2003)
A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community - The Framingham Heart Study
TJ Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Anticoagulation with warfarin downregulates inflammation
PS Maclean et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)
Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?
F Marín et al.
STROKE (2003)
Pharmacogenetics of oral anticoagulants
AK Daly et al.
PHARMACOGENETICS (2003)
Collagen platelet receptor polymorphisms integrin α2β1 C807T and GPVI Q317L and risk of ischemic stroke
VJ Cole et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy
J Hirsh et al.
CIRCULATION (2003)
Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study
AS Go et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2003)
Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis
Y Nakamura et al.
THROMBOSIS RESEARCH (2003)
Warfarin dose adjustments based on CYP2C9 genetic polymorphisms
MW Linder et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2002)
Association of the G20210A mutation in the factor II gene with systemic embolism in nonvalvular atrial fibrillation
V Pengo et al.
AMERICAN JOURNAL OF CARDIOLOGY (2002)
Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?
NAY Chung et al.
STROKE (2002)
Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms
RAS Ariëns et al.
BLOOD (2002)
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
MK Higashi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Activation markers of coagulation and fibrinolysis in twins:: heritability of the prethrombotic state
RAS Ariëns et al.
LANCET (2002)
Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease - The Atherosclerosis Risk in Communities (ARIC) study
N Aleksic et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
Transglutaminase in disease
SY Kim et al.
NEUROCHEMISTRY INTERNATIONAL (2002)
Cerebrovascular events in patients with significant stenosis of the carotid artery are associated with hyperhomocysteinemia and platelet antigen-1 (Leu33Pro) polymorphism
JY Streifler et al.
STROKE (2001)
Platelets and atrial fibrillation
S Kamath et al.
EUROPEAN HEART JOURNAL (2001)
A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism
S Middeldorp et al.
ANNALS OF INTERNAL MEDICINE (2001)
Validation of clinical classification schemes for predicting stroke - Results from the national registry of Atrial Fibrillation
BF Gage et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage
J Corral et al.
BLOOD (2001)
Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage
M Fukuchi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2001)
Hemostatic state and atrial fibrillation (The Framingham Offspring Study)
DL Feng et al.
AMERICAN JOURNAL OF CARDIOLOGY (2001)
Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension
LA Sechi et al.
HYPERTENSION (2000)
Atrial endocardial changes in mitral valve disease: A scanning electron microscopy study
I Goldsmith et al.
AMERICAN HEART JOURNAL (2000)
Pharmacogenetics and the practice of medicine
AD Roses
NATURE (2000)
Share Paper
